Bellerophon Therapeutics Statistics
Share Statistics
Bellerophon Therapeutics has 12.23M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 12.23M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 11.15M |
| Failed to Deliver (FTD) Shares | 1 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 90.45K, so 0.74% of the outstanding shares have been sold short.
| Short Interest | 90.45K |
| Short % of Shares Out | 0.74% |
| Short % of Float | 0.81% |
| Short Ratio (days to cover) | 1.26 |
Valuation Ratios
The PE ratio is -0.43 and the forward PE ratio is -0.02.
| PE Ratio | -0.43 |
| Forward PE | -0.02 |
| PS Ratio | 0 |
| Forward PS | 0 |
| PB Ratio | 3.39 |
| P/FCF Ratio | -0.48 |
| PEG Ratio | n/a |
Enterprise Valuation
Bellerophon Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 1.4, with a Debt / Equity ratio of 0.
| Current Ratio | 1.4 |
| Quick Ratio | 1.4 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | -165.81 |
Financial Efficiency
Return on equity (ROE) is -7.83% and return on capital (ROIC) is -728.98%.
| Return on Equity (ROE) | -7.83% |
| Return on Assets (ROA) | -2.5% |
| Return on Capital (ROIC) | -728.98% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.10M |
| Employee Count | 18 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -2.42M |
| Effective Tax Rate | 0.11 |
Stock Price Statistics
The stock price has increased by -45.95% in the last 52 weeks. The beta is 0.7, so Bellerophon Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.7 |
| 52-Week Price Change | -45.95% |
| 50-Day Moving Average | 0.04 |
| 200-Day Moving Average | 0.05 |
| Relative Strength Index (RSI) | 32.59 |
| Average Volume (20 Days) | 11.56K |
Income Statement
In the last 12 months, Bellerophon Therapeutics had revenue of $0 and earned -$19.83M in profits. Earnings per share was $-2.08.
| Revenue | 0 |
| Gross Profit | -65.00K |
| Operating Income | -22.38M |
| Net Income | -19.83M |
| EBITDA | -22.18M |
| EBIT | - |
| Earnings Per Share (EPS) | -2.08 |
Balance Sheet
The company has $6.92M in cash and $203.00K in debt, giving a net cash position of $6.72M.
| Cash & Cash Equivalents | 6.92M |
| Total Debt | 203.00K |
| Net Cash | 6.72M |
| Retained Earnings | -252.08M |
| Total Assets | 4.98M |
| Working Capital | 3.72M |
Cash Flow
In the last 12 months, operating cash flow was -$17.77M and capital expenditures $0, giving a free cash flow of -$17.77M.
| Operating Cash Flow | -17.77M |
| Capital Expenditures | 0 |
| Free Cash Flow | -17.77M |
| FCF Per Share | -1.86 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
BLPH does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -10400% |
| FCF Yield | -7645.67% |
Analyst Forecast
Currently there are no analyst rating for BLPH.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Feb 10, 2020. It was a backward split with a ratio of 1:15.
| Last Split Date | Feb 10, 2020 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -77.24 |
| Piotroski F-Score | 2 |